Anticholinesterase activity of 3-formylchromone derivatives
- Authors: Pozdnyakov D.I1
-
Affiliations:
- Pyatigorsk medical and pharmaceutical institute
- Issue: Vol 24, No 10 (2021)
- Pages: 31-35
- Section: Articles
- URL: https://journals.eco-vector.com/1560-9596/article/view/112889
- DOI: https://doi.org/10.29296/25877313-2021-10-04
- ID: 112889
Cite item
Abstract
The aim of the study. To evaluate the anticholinesterase activity of 3-formylchromine derivatives in experimental Alzheimer's disease in rats. Material and methods. The work was performed on male Wistar rats that were modeled for Alzheimer's disease by injecting the fragment AB1-42 into the CA1 part of the hippocampus. The test-compounds and the reference drug (ipidacrine, 1 mg / kg, per os) were administered for 60 days. Further, the preservation of the memorable trace in the Morris water maze test and the acetylcholinesterase activity by photometric method in the hippocampus were evaluated. Results. In the course of the work, it was found that among the eighteen studied substances the most pronounced anticholinesterase effect provided by 3-[(E)-3-(3,5-ditret-butyl-4-hydroxy-phenyl)-3-oxo-prop-1-enyl]-6-methoxy-chromene-4-one, the use of which at a dose of 40 mg/kg (oral), reduced the activity of hippocampus acetylcholinesterase by 50.5% (p<0.05) and contributed to the preservation of spatial memory in rats equally with the reference drug. Conclusion. The study demonstrated that the use of 3-formylchromone derivatives and to a greater extent 3-[(E)-3-(3,5-ditret-butyl- 4-hydroxy-phenyl)-3-oxo-prop-1-enyl]-6-methoxy-chromene-4-one contributed to the preservation of a memorable trace in animals with experimentally modeled Alzheimer's disease, which may be associated with the anticholinesterase effect of these compounds.
Full Text
About the authors
D. I Pozdnyakov
Pyatigorsk medical and pharmaceutical institute
Email: pozdniackow.dmitry@yandex.ru
Ph.D. (Pharm.), Associate Professor of Department of Pharmacology with Clinical Pharmacology Course, Head of Living System Laboratory Pyatigorsk, Russia
References
- Wilson R.S., Segawa E., Boyle P.A., Anagnos S.E., Hizel L.P., Bennett D.A. The natural history of cognitive decline in Alzheimer’s disease. Psychol. Aging. 2012; 27: 1008-1017.
- Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016; 12(4): 459-509. doi: 10.1016/j.jalz.2016.03.001. PMID: 27570871.
- Catanesi M. Neuroprotective potential of choline alfoscerate against p-amyloid injury: Involvement of neurotrophic signals. Cell biology international 44.8. 2020: 1734-1744.
- Briggs R., Kennelly S.P., O'Neill D. Drug treatments in Alzheimer's disease. Clin Med (Lond). 2016; 16(3): 247-253. DOI:10.7861/ clinmedicine. 16-3-247.
- Поздняков Д.И., Руковицина В.М., Ларский М.В. Влияние производных 3-формилхромона in vitro на агрегацию частиц р-амилоида и активность тирозиназы. Вопросы биологической, медицинской и фармацевтической химии. 2021; 24(1): 11-15. doi: 10.29296/25877313-2021-01-02
- Onodera K., Kojima J., Wachi M. Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task. Nihon Shinkei Seishin Yakurigaku Zasshi. 1998; 18(2): 33-37.
- Dingova D., Hrabovska A. Metody stanovenia aktivity cholmesteraz [Methods for determination of cholinesterase activity]. Cesk Fysiol. 2015; 64(2): 79-83. Slovak.
- Zhang Y.Y., Yang L.Q., Guo L.M. Effect of phosphatidyl-serine on memory in patients and rats with Alzheimer's disease. Genet. Mol. Res. 2015; 14(3): 9325-9333. doi: 10.4238/2015.
- Hampel H., Mesulam M.M., Cuello A.C. et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018;141(7): 1917-1933. doi: 10.1093/-brain/awy132.
- Mishra Рю, Kumar Аю, Panda G. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018). Bioorg. Med. Chem. 2019; 27(6): 895-930. doi: 10.1016/j.bmc.2019.01.025.
- Sharma K. Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Mol. Med. Rep. 2019; 20(2): 1479-1487. doi: 10.3892/mmr.2019.10374
- Mughal E.U., Javid A., Sadiq A., Murtaza S., Zafar M.N., Khan B.A., Sumrra S.H., Tahir M.N., Kanwal, Khan K.M. Synthesis, structure-activity relationship and molecular docking studies of 3-O-flavonol glycosides as cholinesterase inhibitors. Bioorg. Med. Chem. 2018; 26(12): 3696-3706. doi: 10.1016/j.bmc.2018.05.050.